136 completed, 45 terminated, 13 unknown, 9 withdrawn. 119 Phase 2, 99 Phase 1, 14 Not applicable, 14 Phase 3, 2 Phase 4.
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Haplo-Identical / Cord Blood Transplant - aGVHD, Acute Myelogenous Leukemia | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 36 | 2025-08-13 | 2026-09-15 |
| ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies ICP-248, Azacitidine - Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | Phase 1 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 266 | 2024-12-18 | 2026-08-18 |
| Role of BMP Pathway in MDS Progression Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care - Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Not yet recruiting | Hospices Civils de Lyon | 60 | 2024-01-27 | 2024-01-23 | |
| Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, Dendritic Cell Vaccine - Refractory Leukemia, Relapsed Leukemia | Phase 1 | Withdrawn | Juan C. Ramos, MD | 2023-11-30 | 2023-12-04 | |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. - Hematologic Malignancy, Leukemia | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-11-15 | 2026-10-29 | |
| Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring Web based survey - Breast Cancer, Lung Cancer | Recruiting | Carevive Systems, Inc. | 25 | 2023-07-19 | 2026-10-30 | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| LILRB4 STAR-T Cell Therapy for Monocytic Leukemia LILRB4 STAR-T cells injection - Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia | Not applicable | Completed | Institute of Hematology & Blood Diseases Hospital, China | 1 | 2023-02-16 | 2026-02-11 |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis TBX-2400 - Myelofibrosis, Acute Myelogenous Leukemia | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 10 | 2022-09-01 | 2022-05-03 |
| Diagnosis and Treatment of Periodontal Disease in Patients With AML Scaling and Root Planing - AML, Acute Myelogenous Leukemia | Not applicable | Withdrawn | Masonic Cancer Center, University of Minnesota | 2022-05-01 | 2023-02-22 | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome Gentulizumab - Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 58 | 2021-04-01 | 2026-04-06 |
| A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia SH1573 Capsules - Acute Myelogenous Leukemia | Phase 1 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 41 | 2020-08-04 | 2021-03-19 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia Azacitidine, Venetoclax, Pevonedistat - Acute Myelogenous Leukemia | Phase 1 | Terminated | Medical College of Wisconsin | 16 | 2020-01-13 | 2024-06-04 |
Showing 20 of 222. Sign in to see all of them.
Leukemia, Myeloid, Acute (222) · Myelodysplastic Syndromes (98) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (74) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (52) · Leukemia (45) · Lymphoma, Non-Hodgkin (38) · Hodgkin Disease (34) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Lymphoma (23) · Multiple Myeloma (23) · Recurrence (15) · Myeloproliferative Disorders (12) · Primary Myelofibrosis (11) · Anemia, Aplastic (8) · Anemia, Refractory, with Excess of Blasts (8)
Hemic and Lymphatic Diseases (222) · Neoplasms by Histologic Type (221) · Hematologic Diseases (217) · Neoplasms (216) · Leukemia, Myeloid (215) · Leukemia (177) · Bone Marrow Diseases (116) · Immune System Diseases (84) · Immunoproliferative Disorders (83) · Lymphatic Diseases (82) · Lymphoproliferative Disorders (81) · Leukemia, Lymphoid (75) · Pathological Conditions, Signs and Symptoms (71) · Disease Attributes (70) · Pathologic Processes (70)
fludarabine (28) · Cytarabine (26) · Cyclophosphamide (25) · fludarabine phosphate (19) · Whole-Body Irradiation (18) · Azacitidine (17) · Clofarabine (14) · Busulfan (13) · Mycophenolic Acid (11) · Melphalan (10) · Tacrolimus (10) · Cyclosporine (8) · Decitabine (8) · Gemtuzumab (8) · Interleukin-2 (8)
M.D. Anderson Cancer Center (21) · Masonic Cancer Center, University of Minnesota (13) · Genzyme, a Sanofi Company (6) · Massachusetts General Hospital (6) · Millennium Pharmaceuticals, Inc. (6) · New York Medical College (5) · Center for International Blood and Marrow Transplant Research (4) · Dana-Farber Cancer Institute (4) · National Cancer Institute (NCI) (4) · AbbVie (3) · Beth Israel Deaconess Medical Center (3) · Indiana University (3) · Medical College of Wisconsin (3) · Memorial Sloan Kettering Cancer Center (3) · Wake Forest University Health Sciences (3)
United States (182) · France (10) · Italy (9) · Canada (8) · Germany (8) · Australia (7) · China (6) · South Korea (6) · Spain (5) · Belgium (4) · Israel (3) · Japan (2) · Norway (2) · United Kingdom (2) · Brazil (1)
Amir Fathi, MD (3) · Jacalyn Rosenblatt, MD (3) · Leland Metheny, MD (3) · Dianna Howard, MD (2) · Farhad Ravandi-Kashani, MD (2) · Guillermo Garcia-Manero, MD (2) · Jorge Cortes, MD (2) · Jorge E Cortes, MD (2) · Justin Watts, MD (2) · Mary Horowitz, MD, MS (2) · Mitchell S Cairo, MD (2) · Oystein Bruserud, MD (2) · Renato Bassan, MD (2)
PMID 28877686, PMID 31266741, PMID 31355467, PMID 33917201, PMID 35829925, PMID 11401921, PMID 11753612, PMID 11882484, PMID 11986239, PMID 11986774, PMID 12204832, PMID 12296514, PMID 12415113, PMID 12508246, PMID 12526921, PMID 12571459, PMID 12661004, PMID 12756163, PMID 12951583, PMID 14712141, PMID 14978794, PMID 15026336, PMID 15128601, PMID 15280635, PMID 15298960, PMID 15504444, PMID 15561989, PMID 15613951, PMID 15633596, PMID 15674422, PMID 15729836, PMID 15779869, PMID 15829534, PMID 15951359, PMID 15967214, PMID 16052219, PMID 16103439, PMID 16136170, PMID 16184473, PMID 16190149, PMID 16537719, PMID 16597704, PMID 17035343, PMID 17164381, PMID 17548681, PMID 17596541, PMID 17684147, PMID 17923868, PMID 18291036, PMID 18648011
2008 (4), 2014 (2), U24CA076518 (2), 2015 (1), K12CA167540 (1), P01CA111412 (1), P30CA043703 (1), P50CA206963 (1), R01HL114591 (1), R21CA143805 (1), U01HL069294 (1), U10HL069294 (1), UH2AG056933 (1)